Method for predicting reproductive performance of horse based on transcriptome sequencing technology
The differential genes of horses were detected by transcriptome sequencing technology and fluorescence quantitative PCR were performed, which solved the problem of predicting horse breeding performance in the existing technology, achieved rapid and accurate screening of Kazakhs' reproductive capacity, and enhanced the development potential of the horse industry.
Patent Information
- Application Number
- CN202411417090.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-11
- Publication Date
- 2024-11-22
AI Technical Summary
The existing technology is difficult to predict horse breeding performance quickly and accurately, which affects the development of the horse industry.
Using a transcriptome sequencing method, fluorescence quantitative PCR detection was performed by detecting differential genes related to reproduction (such as COL14A1, COL6A5 and COL3A1) to determine the fluorescence intensity of the sample to predict the reproduction ability of the horse.
The rapid and accurate screening of Kazakh reproductive capacity is achieved, providing an effective method to evaluate the reproductive performance of horses.
Smart Images

Figure CN118995958A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for predicting horse reproductive performance based on transcriptome sequencing technology. Background Art
[0002] Equine animals have a long growth cycle, late sexual maturity, and a long breeding cycle, which has become a key step restricting the high-quality and high-level development of the horse industry. At the same time, excellent retired mares are a valuable resource in the development of domestic horses. The offspring of mares that have achieved competition results are not only excellent in performance but also extremely valuable. Equine breeding is an important economic trait in horse production and a quantitative trait regulated by multiple genes. Mares with high reproductive performance are favored by breeders. Therefore, the study of reproductive performance of equine animals has always been the focus of research by animal husbandry scholars in my country.
[0003] Therefore, detecting or predicting the reproductive capacity of equine animals through RNA detection methods has become an important research direction. Summary of the invention
[0004] In view of the above technical problems existing in the prior art, the present invention provides a method for identifying the reproductive capacity of Kazakh horses based on transcriptome, and detects or predicts the reproductive capacity of Kazakh horses based on RNA expression detection, so as to screen Kazakh horses.
[0005] The present invention discloses a method for predicting horse reproductive performance based on transcriptome sequencing technology, comprising the following steps: obtaining differential genes related to reproduction in the transcriptome of Kazakh horses; obtaining a primer set based on the differential genes; performing fluorescence quantitative PCR detection on the differential genes of the sample using the primer set to obtain fluorescence intensity; judging whether the fluorescence intensity is within a first threshold interval or greater than a second threshold; if so, predicting that the reproductive capacity of the sample is strong; if not, predicting that the reproductive capacity of the sample is weak.
[0006] Preferably, the differentially expressed genes include any one of the following genes or a combination thereof: COL14A1, COL6A5 and COL3A1.
[0007] Preferably, the differential gene is an up-regulated gene, and the fluorescence intensity of the sample to be tested, the standard positive sample and the standard negative sample are obtained respectively;
[0008] Determine whether the fluorescence intensity of the sample to be tested meets any of the following conditions or their combination:
[0009] The fluorescence intensity of the sample to be tested is greater than the fluorescence intensity of the standard positive sample*A, and greater than the fluorescence intensity of the standard negative sample, where A is expressed as a coefficient;
[0010] If it is satisfied, it is judged that the reproductive capacity of the sample to be tested is strong.
[0011] Preferably, the method of grading reproductive capacity comprises:
[0012] According to the fluorescence intensity of the standard positive sample and the standard negative sample, the fluorescence intensity is divided into multiple levels and corresponding threshold intervals;
[0013] The sample to be tested is matched with the threshold interval to obtain the level of the sample to be tested.
[0014] Preferably, the primer set includes Seq ID No.:3 and Seq ID No.:4.
[0015] Preferably, the primer set also includes Seq ID No.:1 and Seq ID No.:2.
[0016] Preferably, the primer set also includes a Taqman probe.
[0017] Preferably, the method for obtaining differential genes comprises:
[0018] Establish Kazakh horse groups, including Group 1 (Group B) and Group 2 (Group Y), where Group 1 has stronger reproductive capacity than Group 2;
[0019] Extracting RNA from each sample in the group, respectively, wherein the RNA includes coding RNA and non-coding RNA;
[0020] Sequencing the RNA to obtain offline data;
[0021] The offline data are analyzed to obtain differentially expressed genes.
[0022] Preferably, the method for obtaining the off-board data includes:
[0023] Remove ribosomal RNA from RNA of each sample;
[0024] The obtained RNA is randomly broken into short fragments;
[0025] The fragmented RNA was used as a template to synthesize the first strand of cDNA using six-base random primers;
[0026] Add buffer, dNTPs, RNase H and DNA polymerase I to the first strand of cDNA to synthesize the second strand of cDNA;
[0027] After the cDNA is purified and eluted with EB buffer, it is end-repaired and base A is added, and then sequencing adapters are added;
[0028] Degradation of the second strand by UNG enzyme;
[0029] After fragment size selection by agarose gel electrophoresis, PCR amplification was performed to obtain a sequencing library;
[0030] The sequencing library is sequenced by a sequencer to obtain offline data.
[0031] Preferably, the method for analyzing the off-board data includes:
[0032] Filter the offline data to obtain clean data;
[0033] The read length of the clean data was aligned to the reference genome using the tool Hisat2, and the transcripts were reconstructed using stringtie to obtain known transcripts and new transcripts;
[0034] Predict the coding capacity of new transcripts to obtain newly predicted long non-coding RNAs and known genes;
[0035] After analyzing the mRNA and lncRNA in the samples respectively, the association analysis between lncRNA and mRNA was performed.
[0036] Compared with the prior art, the beneficial effects of the present invention are: the fluorescence intensity of fluorescent quantitative PCR reflects the RNA expression level of the differentially expressed genes; the reproductive capacity of the sample is predicted or detected by the RNA expression level, thereby realizing rapid and accurate screening of Kazakh horses. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 is the expression abundance distribution diagram;
[0038] Figure 2 is the heat map of correlation coefficients between samples;
[0039] Figure 3 It is a bar graph of differential gene analysis;
[0040] Figure 4 It is a volcano plot of differential gene analysis;
[0041] Figure 5 is a heat map of differential gene analysis;
[0042] Figure 6 is the enrichment analysis histogram of annotations;
[0043] Figure 7 is the annotated enrichment analysis dot plot;
[0044] Figure 8 It is the amplification curve of fluorescent PCR;
[0045] Fig. 9 It is the melting curve diagram of fluorescent PCR;
[0046] Fig.10 It is a bar graph comparing the relative fluorescence intensity of group B and group Y. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0048] The present invention is further described in detail below in conjunction with the accompanying drawings:
[0049] The first aspect of the present invention provides a method for predicting horse reproductive performance based on transcriptome sequencing technology, comprising the following steps:
[0050] Step S1: Establish a Kazakh horse group, including Group B and Group Y. The reproductive capacity of Group B is stronger than that of Group Y. In a specific embodiment, Group B and Group Y each have 10 samples.
[0051] Step S2: extracting RNA from each sample in the group respectively, wherein the RNA includes coding RNA (coding RNA) and non-coding RNA (ncRNA).
[0052] Step S3: Sequence the RNA to obtain offline data.
[0053] Step S4: Analyze the offline data to obtain differentially expressed genes.
[0054] More specifically, the differentially expressed genes include up-regulated genes and down-regulated genes.
[0055] Step S5: constructing a primer set based on the differential genes; and using the primer set to perform fluorescence quantitative PCR detection on the differential genes of the sample to obtain fluorescence intensity.
[0056] Step S6: Determine whether the fluorescence intensity is within a first threshold range.
[0057] Step S6: If yes, predict that the sample has strong reproductive capacity.
[0058] Step S8: If not, predict that the reproductive capacity of the sample is weak.
[0059] The fluorescence intensity reflects the RNA expression level of the differentially expressed genes; the reproductive capacity of the samples can be predicted or detected by RNA expression level, thus enabling rapid and accurate screening of Kazakh horses.
[0060] In specific tests, the differentially expressed genes found included COL14A1, COL6A5 and COL3A1.
[0061] In a specific test, for upregulated genes, the fluorescence intensity can be compared with the fluorescence intensity of the standard positive sample and the standard negative sample. If the fluorescence intensity of the sample is greater than the fluorescence intensity of the standard positive sample*0.8 (as the second threshold) and greater than the fluorescence intensity of the standard negative sample, the sample is considered to have a strong reproductive capacity.
[0062] For down-regulated genes, on the contrary, the fluorescence intensity needs to be less than the fluorescence intensity of the standard positive sample*1.2.
[0063] Among them, the reproductive capacity can also be graded according to the fluorescence intensity:
[0064] According to the fluorescence intensity of the standard positive sample and the standard negative sample, they are divided into multiple levels and corresponding threshold intervals; the sample to be tested is matched with the threshold interval to obtain the level of the sample to be tested.
[0065] For example, the fluorescence intensity of the standard positive sample*(0.5-0.8) is in the third level, the fluorescence intensity of the standard positive sample*(0.8-1) is in the fourth level, and the fluorescence intensity greater than the standard positive sample is in the fifth level. But it is not limited to this.
[0066] Steps S2 and S3 include the following steps:
[0067] Step 201: Extract total RNA from each sample.
[0068] Step 202: remove the ribosomal RNA to retain all coding RNA (coding RNA) and non-coding RNA (ncRNA) to the maximum extent.
[0069] Step 203: randomly breaking the obtained RNA into short fragments (RNA fragmentation, 200-500 nt).
[0070] Step 204: Using the fragmented RNA as a template, a random hexamers is used to synthesize the first strand of cDNA.
[0071] Step 205: Then, a buffer, dNTPs (dUTP instead of dTTP), RNase H and DNA polymerase I are added to synthesize the second strand of cDNA, which is purified by QiaQuick PCR kit and eluted with EB buffer, and then the ends are repaired, base A is added, and sequencing adapters are added.
[0072] Step 206: Degrading the second strand by UNG (Uracil-N-Glycosylase) enzyme.
[0073] Step 207: Perform fragment size selection by agarose gel electrophoresis, perform PCR amplification, and obtain a sequencing library.
[0074] Step 208: The constructed sequencing library is sequenced using Illumina HiSeqTM 4000 to obtain raw data.
[0075] In step S4, the data analysis method includes the following steps:
[0076] Step 401: Filter the offline data to obtain clean data.
[0077] The statistics of the number of mRNA detected in each sample in the clean data are shown in Table 1.
[0078] Step 402: The reads of the clean data are aligned to the reference genome using the tool Hisat2, and the transcripts are reconstructed using stringtie to obtain known transcripts and new transcripts.
[0079] Step 403: Use CPC, CNCI and other software to predict the coding ability of the new transcript to obtain newly predicted long non-coding RNA (lncRNA) and known genes.
[0080] Step 404: Then analyze the mRNA and lncRNA in the sample respectively, and finally perform lncRNA-mRNA association analysis.
[0081] More specifically, mRNA analysis includes mRNA differential expression, sample relationship analysis, differential gene function enrichment analysis, and expression pattern cluster analysis. lncRNA analysis includes lncRNA type statistics, lncRNA differential expression, expression abundance distribution analysis, lncRNA family analysis, and lncRNA precursor prediction. Figure 1 , where FPKM value (Fragments Per Kilobase per Million) represents the abundance of gene expression, and the vertical axis represents density. Association analysis includes: antisense analysis, cis target gene prediction, trans target gene prediction and target gene function enrichment analysis. The results of enrichment analysis are shown in Table 2, Figure 6 and Figure 7 , where FC (FoldChange) represents the change value and P value represents the significance.
[0082] In addition, a correlation heat map analysis was performed. The expression level of each gene (the entire gene set) in any two samples was taken, and the Pierce correlation coefficient between each two samples was calculated. These correlation coefficients were then used to visually display the correlation between any two samples in the form of a heat map. Figure 2 Intergroup difference analysis: The input data for gene differential expression analysis is the read count data obtained in the gene expression level analysis. The analysis is performed using DESeq2 software. The analysis is mainly divided into three parts: 1) normalization of read count; 2) calculation of hypothesis test probability (pvalue) based on the model; 3) finally, multiple hypothesis testing correction is performed to obtain the FDR value (false discovery rate). For analysis of the bar graph, see Figure 3 , volcano map see Figure 4 , heat map see Figure 5 .
[0083] Step 405: Perform structural analysis on the transcript obtained in step 402, including gene structure optimization, variable splicing analysis, etc.
[0084] Table 1
[0085] sample Reference sequence Detected reference sequence (%) New Gene Detection of novel genes (%) Total genes Detected genes (%) all 20497 17352(84.66%) 198 198(100.00%) 20695 17550(84.80%) Group-B-1 20497 14680(71.62%) 198 172(86.87%) 20695 14852(71.77%) Group-B-2 20497 14317(69.85%) 198 172(86.87%) 20695 14489(70.01%) Group-B-3 20497 14988(73.12%) 198 182(91.92%) 20695 15170(73.30%) Group-B-4 20497 14628(71.37%) 198 171(86.36%) 20695 14799(71.51%) Group-B-5 20497 14986(73.11%) 198 174(87.88%) 20695 15160(73.25%) Group-B-6 20497 14615(71.30%) 198 174(87.88%) 20695 14789(71.46%) Group-B-7 20497 14668(71.56%) 198 166(83.84%) 20695 14834(71.68%) Group-B-8 20497 14663(71.54%) 198 168(84.85%) 20695 14831(71.66%) Group-B-9 20497 14904(72.71%) 198 181(91.41%) 20695 15085(72.89%) Group-B-10 20497 14980(73.08%) 198 173(87.37%) 20695 15153(73.22%) Group-Y-1 20497 14520(70.84%) 198 172(86.87%) 20695 14692(70.99%) Group-Y-2 20497 14372(70.12%) 198 179(90.40%) 20695 14551(70.31%) Group-Y-3 20497 14526(70.87%) 198 172(86.87%) 20695 14698(71.02%) Group-Y-4 20497 14595(71.21%) 198 174(87.88%) 20695 14769(71.37%) Group-Y-5 20497 14692(71.68%) 198 177(89.39%) 20695 14869(71.85%) Group-Y-6 20497 14854(72.47%) 198 170(85.86%) 20695 15024(72.60%) Group-Y-7 20497 14497(70.73%) 198 170(85.86%) 20695 14667(70.87%) Group-Y-8 20497 14776(72.09%) 198 175(88.38%) 20695 14951(72.24%) Group-Y-9 20497 15022(73.29%) 198 177(89.39%) 20695 15199(73.44%) Group-Y-10 20497 14866(72.53%) 198 176(88.89%) 20695 15042(72.68%)
[0086] Table 2
[0087]
[0088] Some of the annotation results are as follows:
[0089] GO:0044707;single-multicellular organism process;221;4408;3.16E-08;2.78E-06;
[0090] ENSECAG00000000134(MEGF9);ENSECAG00000000179(SCN1B);ENSECAG00000000214(IL18RAP);ENSECAG00000000512(LBH);ENSECAG00000000658(GPNMB);ENSECAG00000000787(ADAMTS16);ENSECAG00000000794(EMB);ENSECAG00000000874(ACKR1);ENSECAG00000000875(FOXL1);ENSECAG00000000942(ACKR3);ENSECAG00000001174(TNF);ENSECAG00000001214(CCR2);ENSECAG00000001863(B3GNT5);ENSECAG00000002171(FLT3);ENSECAG00000003106(C3AR1);ENSECAG00000003955(TRPV2);ENSECAG00000004162(EVI2B);ENSECAG00000004592(DUSP4);ENSECAG00000005704(CARD11);ENSECAG00000005787(TBX18);ENSECAG00000005844(RGL3);ENSECAG00000005856(LY9);ENSECAG00000006176(CNTFR);ENSECAG00000006253(ICOS);ENSECAG00000006456(IL17B);ENSECAG00000006603(HLA-DOA);ENSECAG00000006647(GFI1);ENSECAG00000007133(TPPP3);ENSECAG00000007138(BMP5);ENSECAG00000007192(PTPRC);ENSECAG00000007294(PIGT);ENSECAG00000007441(IKZF3);ENSECAG00000007539(TRPM1);ENSECAG00000007614(CLDN3);ENSECAG00000007828(GDPD2);ENSECAG00000007883(TLR7);ENSECAG00000008085(OTOA);ENSECAG00000008107(FERMT3);ENSECAG00000008236(APOE);ENSECAG00000008274(CLEC4E);ENSECAG00000008296(CCBE1);ENSECAG00000008354(PM20D1);ENSECAG00000008555(LTB);ENSECAG00000008765(MYCL);ENSECAG00000008830(WNT5A);ENSECAG00000008979(-);ENSECAG00000009049(CD4);ENSECAG00000009462(COL14A1);ENSECAG00000009530(ITK);ENSECAG00000009535(FCER1G);ENSECAG00000009761(DOCK2);ENSECAG00000009896(SERPINB1);ENSECAG00000009989(CHAC1);ENSECAG00000010025(GPC3);ENSECAG00000010166(PYCARD);ENSECAG00000010263(SASH3);ENSECAG00000010267(CD44);ENSECAG00000010291(LRRC17);ENSECAG00000010380(HAP1);ENSECAG00000010454(MYOC);ENSECAG00000010500(ITGA4);ENSECAG00000010523(ADGRG3);ENSECAG00000010716(CLEC6A);ENSECAG00000010865(JHY);ENSECAG00000011067(CAPN3);ENSECAG00000011090(PTPN18);ENSECAG00000011180(CD6);ENSECAG00000011334(SALL1);ENSECAG00000011338(ABCB5);ENSECAG00000011439(DHX58);ENSECAG00000011511(PGR);ENSECAG00000011570(PLXNA4);ENSECAG00000011871(DNER);ENSECAG00000011891(NTN4);ENSECAG00000012327(IL34);ENSECAG00000012370(NPTX2);ENSECAG00000012616(GRIN3A);ENSECAG00000012671(PRTG);ENSECAG00000012733(COL6A5);ENSECAG00000012771(ALOXE3);ENSECAG00000012863(ITGA8);ENSECAG00000012921(ALPK2);ENSECAG00000012930(ALOX5);ENSECAG00000013428(ID4);ENSECAG00000013429(SLITRK6);ENSECAG00000013514(DUSP5);ENSECAG00000013604(MDM2);ENSECAG00000013722(PLD3);ENSECAG00000013747(AIF1);ENSECAG00000013748(KRT25);ENSECAG00000013788(ARHGDIB);ENSECAG00000013874(SPARC);ENSECAG00000013961(-);ENSECAG00000013986(TMEM178A);ENSECAG00000014080(SCN3A);ENSECAG00000014312(PRKCZ);ENSECAG00000014379(BMP3);ENSECAG00000014480(AIM2);ENSECAG00000014580(KCNMB3);ENSECAG00000014626(WNT8A);ENSECAG00000014742(GPAM);ENSECAG00000014771(LOX);ENSECAG00000014896(VAV1);ENSECAG00000015050(CTH);ENSECAG00000015063(ADGRG6);ENSECAG00000015261(IL18);ENSECAG00000015270(TREM2);ENSECAG00000015342(CXCL8);ENSECAG00000015382(NLRP3);ENSECAG00000015449(IRF8);ENSECAG00000015460(HCLS1);ENSECAG00000015730(NAPSA);ENSECAG00000016111(CDH6);ENSECAG00000016176(NDP);ENSECAG00000016549(FASLG);ENSECAG00000016717(NPY1R);ENSECAG00000016786(JPH2);ENSECAG00000016808(IRF4);ENSECAG00000016927(SULF1);ENSECAG00000017027(SFRP2);ENSECAG00000017144(CTNNBL1);ENSECAG00000017181(PTGS2);ENSECAG00000017267(KLRK1);ENSECAG00000017268(ATP8A2);ENSECAG00000017337(PDE6B);ENSECAG00000017433(TNC);ENSECAG00000017662(NLRP12);ENSECAG00000017668(KERA);ENSECAG00000017794(IRF1);ENSECAG00000017998(DHCR24);ENSECAG00000018028(TLR2);ENSECAG00000018091(NR0B1);ENSECAG00000018190(CD3D);ENSECAG00000018339(IKZF1);ENSECAG00000018419(ANXA3);ENSECAG00000018924(PTK2B);ENSECAG00000018927(ANGPTL4);ENSECAG00000018996(PLEK);ENSECAG00000019036(MMP16);ENSECAG00000019087(CTSK);ENSECAG00000019306(ZNF653);ENSECAG00000019437(CD2);ENSECAG00000019442(CYP1B1);ENSECAG00000019508(COL8A1);ENSECAG00000019524(CNMD);ENSECAG00000019551(CXCL12);ENSECAG00000019559(WHRN);ENSECAG00000019853(AMIGO2);ENSECAG00000019910(PDLIM2);ENSECAG00000019932(-);ENSECAG00000020158(CD247);ENSECAG00000020193(TGFBI);ENSECAG00000020410(FREM2);ENSECAG00000020413(DCN);ENSECAG00000020474(CYP19A1);ENSECAG00000020489(SLITRK2);ENSECAG00000020491(CD84);ENSECAG00000020578(PDCD1LG2);ENSECAG00000020587(GM2A);ENSECAG00000020677(LHCGR);ENSECAG00000020749(SCN2A);ENSECAG00000020769(FGF1);ENSECAG00000020892(TLR10);ENSECAG00000020984(BTK);ENSECAG00000021052(EOMES);ENSECAG00000021088(GDF9);ENSECAG00000021206(HAS2);ENSECAG00000021330(HMGCR);ENSECAG00000021367(POPDC3);ENSECAG00000021603(LCP2);ENSECAG00000021639(C6);ENSECAG00000021651(NPC1);ENSECAG00000021944(COCH);ENSECAG00000022186(-);ENSECAG00000022329(LRRC4C);ENSECAG00000022408(CD244);ENSECAG00000022446(PLD4);ENSECAG00000022551(SLC8A3);ENSECAG00000022724(CYP26B1);ENSECAG00000022744(RHBDD3);ENSECAG00000022853(CD28);ENSECAG00000022939(S100A1);ENSECAG00000023168(TRPC3);ENSECAG00000023234(CPTP);ENSECAG00000023256(LCK);ENSECAG00000023341(DHCR7);ENSECAG00000023357(COL9A3);ENSECAG00000023363(SLC26A2);ENSECAG00000023430(TRPM2);ENSECAG00000023448(GPR18);ENSECAG00000023457(GPR183);ENSECAG00000023599(HPSE);ENSECAG00000023915(FAM210B);ENSECAG00000024048(TIPARP);ENSECAG00000024062(DDX60L);ENSECAG00000024068(KIAA0319);ENSECAG00000024128(CNTNAP1);ENSECAG00000024140(TMEM91);ENSECAG00000024367(CASP1);ENSECAG00000024374(ERBB3);ENSECAG00000024394(SLC6A17);ENSECAG00000024403(DPYSL5);ENSECAG00000024457(SPI1);ENSECAG00000024459(MARK1);ENSECAG00000024540(HSPB7);ENSECAG00000024570(BRINP2);ENSECAG00000024611(NTF3);ENSECAG00000024623(ATP1A1);ENSECAG00000024769(COL3A1);ENSECAG00000024788(CORO1A);ENSECAG00000024845(PI16);ENSECAG00000029287(-);ENSECAG00000029465(CHI3L1);ENSECAG00000032515(CEBPA);ENSECAG00000032667(INA);ENSECAG00000032767(FMR1);ENSECAG00000032992(TIAM1);ENSECAG00000039279(TBX19);ENSECAG00000040744(TYROBP);MSTRG.31088(MNDA);MSTRG.6847(MYO15A)。;
[0091] GO:0048513;126;2389;9.39E-06;0.000303179;
[0092] ENSECAG00000000134(MEGF9);ENSECAG00000000512(LBH);ENSECAG00000000787(ADAMTS16);ENSECAG00000000875(FOXL1);ENSECAG00000001174(TNF);ENSECAG00000001863(B3GNT5);ENSECAG00000002171(FLT3);ENSECAG00000004162(EVI2B);ENSECAG00000005704(CARD11);ENSECAG00000005787(TBX18);ENSECAG00000005856(LY9);ENSECAG00000006176(CNTFR);ENSECAG00000006603(HLA-DOA);ENSECAG00000006647(GFI1);ENSECAG00000007133(TPPP3);ENSECAG00000007138(BMP5);ENSECAG00000007192(PTPRC);ENSECAG00000007441(IKZF3);ENSECAG00000007539(TRPM1);ENSECAG00000008274(CLEC4E);ENSECAG00000008296(CCBE1);ENSECAG00000008555(LTB);ENSECAG00000008765(MYCL);ENSECAG00000008830(WNT5A);ENSECAG00000009049(CD4);ENSECAG00000009462(COL14A1);ENSECAG00000009530(ITK);ENSECAG00000009535(FCER1G);ENSECAG00000009761(DOCK2);ENSECAG00000010025(GPC3);ENSECAG00000010263(SASH3);ENSECAG00000010267(CD44);ENSECAG00000010291(LRRC17);ENSECAG00000010454(MYOC);ENSECAG00000010523(ADGRG3);ENSECAG00000010865(JHY);ENSECAG00000011334(SALL1);ENSECAG00000011338(ABCB5);ENSECAG00000011511(PGR);ENSECAG00000011570(PLXNA4);ENSECAG00000011871(DNER);ENSECAG00000011891(NTN4);ENSECAG00000012327(IL34);ENSECAG00000012733(COL6A5);ENSECAG00000012771(ALOXE3);ENSECAG00000012863(ITGA8);ENSECAG00000012921(ALPK2);ENSECAG00000012930(ALOX5);ENSECAG00000013429(SLITRK6);ENSECAG00000013604(MDM2);ENSECAG00000013748(KRT25);ENSECAG00000013874(SPARC);ENSECAG00000013986(TMEM178A);ENSECAG00000014312(PRKCZ);ENSECAG00000014626(WNT8A);ENSECAG00000014771(LOX);ENSECAG00000014896(VAV1);ENSECAG00000015063(ADGRG6);ENSECAG00000015261(IL18);ENSECAG00000015270(TREM2);ENSECAG00000015342(CXCL8);ENSECAG00000015449(IRF8);ENSECAG00000015460(HCLS1);ENSECAG00000016176(NDP);ENSECAG00000016549(FASLG);ENSECAG00000016717(NPY1R);ENSECAG00000016786(JPH2);ENSECAG00000016808(IRF4);ENSECAG00000016927(SULF1);ENSECAG00000017027(SFRP2);ENSECAG00000017181(PTGS2);ENSECAG00000017268(ATP8A2);ENSECAG00000017337(PDE6B);ENSECAG00000017433(TNC);ENSECAG00000017668(KERA);ENSECAG00000017794(IRF1);ENSECAG00000017998(DHCR24); ENSECAG00000018091(NR0B1); ENSECAG00000018190(CD3D); ENSECAG00000018339(IKZF1); ENSECAG00000018924( PTK2B); ENSECAG00000018996(PLEK); ENSECAG00000019087(CTSK); ENSECAG00000019442(CYP1B1); ENSECAG00000019508(COL8A1); 19559(WHRN);ENSECAG00000019853(AMIGO2);ENSECAG00000019910(PDLIM2);ENSECAG00000020410(FREM2);ENSECAG00000020474(CYP19A1);ENSECAG00000020677(LHCGR);ENSECAG00000020769(FGF1);ENSECAG00000020984(BTK);ENSECAG00000021052(EOMES);ENSECAG00000021088(GDF9);EN SECAG00000021206(HAS2); ENSECAG00000021367(POPDC3); ENSECAG00000021944(COCH); ENSECAG00000022446(PLD4); ENSECAG00000022551(SLC8A) 3). 1(DHCR7);ENSECAG00000023357(COL9A3);ENSECAG00000023430(TRPM2);ENSECAG00000023448(GPR18);ENSECAG00000023457(GPR183);ENSECAG00 000023599(HPSE);ENSECAG00000023915(FAM210B);ENSECAG00000024048(TIPARP);ENSECAG00000024140(TMEM91);ENSECAG00000024374(ERBB3);ENSECAG00000024394(SLC6A17);ENSECAG00000024457(SPI1);ENSECAG00000024540(HSPB7);ENSECAG00000024769(COL3A1);ENSECAG00000024845(PI16);ENSECAG00000029287(-);ENSECAG00000029465(CHI3L1);ENSECAG00000032515(CEBPA);ENSECAG00000032992(TIAM1);ENSECAG00000039279(TBX19);ENSECAG00000040744(TYROBP);MSTRG.31088(MNDA)。;
[0093] GO:0048731;system development;163;3293;1.26E-05;0.000392179;ENSECAG00000000134(MEGF9);ENSECAG00000000179(SCN1B);ENSECAG00000000512(LBH);ENSECAG00000000787(ADAMTS16);ENSECAG00000000794(EMB);ENSECAG00000000875(FOXL1);ENSECAG00000000942(ACKR3);ENSECAG00000001174(TNF);ENSECAG00000001863(B3GNT5);ENSECAG00000002171(FLT3);ENSECAG00000003106(C3AR1);ENSECAG00000003955(TRPV2);ENSECAG00000004162(EVI2B);ENSECAG00000005704(CARD11);ENSECAG00000005787(TBX18);ENSECAG00000005856(LY9);ENSECAG00000006176(CNTFR);ENSECAG00000006253(ICOS);ENSECAG00000006603(HLA-DOA);ENSECAG00000006647(GFI1);ENSECAG00000007133(TPPP3);ENSECAG00000007138(BMP5);ENSECAG00000007192(PTPRC);ENSECAG00000007294(PIGT);ENSECAG00000007441(IKZF3);ENSECAG00000007539(TRPM1);ENSECAG00000007614(CLDN3);ENSECAG00000008236(APOE);ENSECAG00000008274(CLEC4E);ENSECAG00000008296(CCBE1);ENSECAG00000008555(LTB);ENSECAG00000008765(MYCL);ENSECAG00000008830(WNT5A);ENSECAG00000009049(CD4);ENSECAG00000009462(COL14A1);ENSECAG00000009530(ITK);ENSECAG00000009535(FCER1G);ENSECAG00000009761(DOCK2);ENSECAG00000009989(CHAC1);ENSECAG00000010025(GPC3);ENSECAG00000010263(SASH3);ENSECAG00000010267(CD44);ENSECAG00000010291(LRRC17);ENSECAG00000010380(HAP1);ENSECAG00000010454(MYOC);ENSECAG00000010523(ADGRG3);ENSECAG00000010865(JHY);ENSECAG00000011334(SALL1);ENSECAG00000011338(ABCB5);ENSECAG00000011511(PGR);ENSECAG00000011570(PLXNA4);ENSECAG00000011871(DNER);ENSECAG00000011891(NTN4);ENSECAG00000012327(IL34);ENSECAG00000012616(GRIN3A);ENSECAG00000012671(PRTG);ENSECAG00000012733(COL6A5);ENSECAG00000012771(ALOXE3);ENSECAG00000012863(ITGA8);ENSECAG00000012921(ALPK2);ENSECAG00000012930(ALOX5);ENSECAG00000013429(SLITRK6);ENSECAG00000013604(MDM2);ENSECAG00000013748(KRT25);ENSECAG00000013874(SPARC);ENSECAG00000013986(TMEM178A);ENSECAG00000014312(PRKCZ);ENSECAG00000014626(WNT8A);ENSECAG00000014771(LOX);ENSECAG00000014896(VAV1);ENSECAG00000015050(CTH);ENSECAG00000015063(ADGRG6);ENSECAG00000015261(IL18);ENSECAG00000015270(TREM2);ENSECAG00000015342(CXCL8);ENSECAG00000015449(IRF8);ENSECAG00000015460(HCLS1);ENSECAG00000016176(NDP);ENSECAG00000016549(FASLG);ENSECAG00000016717(NPY1R);ENSECAG00000016786(JPH2);ENSECAG00000016808(IRF4);ENSECAG00000016927(SULF1);ENSECAG00000017027(SFRP2);ENSECAG00000017144(CTNNBL1);ENSECAG00000017181(PTGS2);ENSECAG00000017268(ATP8A2);ENSECAG00000017337(PDE6B);ENSECAG00000017433(TNC);ENSECAG00000017668(KERA);ENSECAG00000017794(IRF1);ENSECAG00000017998(DHCR24);ENSECAG00000018091(NR0B1);ENSECAG00000018190(CD3D);ENSECAG00000018339(IKZF1);ENSECAG00000018419(ANXA3);ENSECAG00000018924(PTK2B);ENSECAG00000018927(ANGPTL4);ENSECAG00000018996(PLEK);ENSECAG00000019036(MMP16);ENSECAG00000019087(CTSK);ENSECAG00000019306(ZNF653);ENSECAG00000019442(CYP1B1);ENSECAG00000019508(COL8A1);ENSECAG00000019524(CNMD);ENSECAG00000019551(CXCL12);ENSECAG00000019559(WHRN);ENSECAG00000019853(AMIGO2);ENSECAG00000019910(PDLIM2);ENSECAG00000020193(TGFBI);ENSECAG00000020410(FREM2);ENSECAG00000020413(DCN);ENSECAG00000020474(CYP19A1);ENSECAG00000020489(SLITRK2);ENSECAG00000020677(LHCGR);ENSECAG00000020749(SCN2A);ENSECAG00000020769(FGF1);ENSECAG00000020984(BTK);ENSECAG00000021052(EOMES);ENSECAG00000021088(GDF9);ENSECAG00000021206(HAS2);ENSECAG00000021367(POPDC3);ENSECAG00000021639(C6);ENSECAG00000021944(COCH);ENSECAG00000022186(-);ENSECAG00000022329(LRRC4C);ENSECAG00000022446(PLD4);ENSECAG00000022551(SLC8A3);ENSECAG00000022724(CYP26B1);ENSECAG00000022744(RHBDD3);ENSECAG00000022853(CD28);ENSECAG00000022939(S100A1);ENSECAG00000023256(LCK);ENSECAG00000023341(DHCR7);ENSECAG00000023357(COL9A3);ENSECAG00000023430(TRPM2);ENSECAG00000023448(GPR18);ENSECAG00000023457(GPR183);ENSECAG00000023599(HPSE);ENSECAG00000023915(FAM210B);ENSECAG00000024048(TIPARP);ENSECAG00000024068(KIAA0319);ENSECAG00000024128(CNTNAP1);ENSECAG00000024140(TMEM91);ENSECAG00000024374(ERBB3);ENSECAG00000024394(SLC6A17);ENSECAG00000024403(DPYSL5);ENSECAG00000024457(SPI1);ENSECAG00000024459(MARK1);ENSECAG00000024540(HSPB7);ENSECAG00000024570(BRINP2); ENSECAG00000024611(NTF3); ENSECAG00000024769(COL3A1); EN SECAG00000024845(PI16); ENSECAG00000029287(-); ENSECAG00000029465(CHI3L1); ENSECAG00 000032515(CEBPA); ENSECAG00000032667(INA); ENSECAG00000032767(FMR1); ENSECAG00000032 992(TIAM1); ENSECAG00000039279(TBX19); ENSECAG00000040744(TYROBP); MSTRG.31088(MNDA). ;
[0094] Organismal Systems; Digestive system; Protein digestion and absorption; 10; 105; 0.007699501; 6.40E-02; ko04974;
[0095] ENSECAG00000022551(SLC8A3); ENSECAG00000021600(XPNPEP2); ENSECAG00000023357(COL9A3); ENSECAG00000009887(COL21A1); ENSECAG00000009462(COL14) A1); ENSECAG00000024769(COL3A1); ENSECAG00000011035(COL9A1); ENSECAG00000012733(COL6A5); ENSECAG00000040942(-); ENSECAG00000024623(ATP1A1);
[0096] K05849+K14208+K08131+K16629+K08133+K19720+K08131+K06238+K06238+K01539.
[0097] Among them, the main differentially expressed genes are: COL14A1, COL6A5 and COL3A1, but are not limited to these.
[0098] In step S5, real-time quantitative PCR is a technique that adds fluorescent groups to the PCR reaction system and realizes real-time monitoring of the entire PCR process through the continuous accumulation of fluorescent signals. Since there is a linear relationship between the Ct value of the template and the starting copy number of the template during the exponential period of PCR amplification, quantitative analysis can be performed.
[0099] Primers were designed using COL14A1 as the detection gene. According to the gene sequence information, qPCR amplification primers were designed using the primer design software Primer5, and the primers were synthesized. See Table 3 for primer design, and Taqman probes can be used as primer probes, which will not be described in detail in the present invention. See Table 4 for data quality control standards.
[0100] Table 3
[0101]
[0102] Table 4
[0103] Quality Control Projects Specific content result Amplification curve Amplification curve is good S-shaped qualified Melting curve Melting curve is single and peak shape is normal qualified Negative quality control NTC Ct value ≥35 qualified Ct difference The data repeatability error of CT value ≤30 is ≤0.5 qualified
[0104] PCR amplification curves refer to Figure 8 , the ordinate is the relative fluorescence intensity △Rn, and the abscissa is the cycle number; for the melting curve, see Fig. 9 , the horizontal axis is temperature °C, and the vertical axis is fluorescence intensity (Derivative Reporter, -Rn′); the relative fluorescence intensity comparison between group B and group Y can be found in Fig.10 The ordinate is the relative value of fluorescence intensity, with Group B as 1.
[0105] The present invention detects the expression levels of key nodes in the groups by RT-qPCR. The results show that the expression trends of key node genes in each group are consistent with the RNA-seq data, indicating that the RNA sequencing data is reliable. The differential genes COL14A1 and the like in the present invention are key core genes that affect the reproductive capacity of equine animals. The method of the present invention can effectively predict and identify the reproductive capacity of Kazakh horses.
[0106] The second aspect of the present invention also provides a system for implementing the above method, the system comprising a detection module and an analysis module, the detection module uses the primer set to perform fluorescence quantitative PCR detection on the differential gene of the sample to obtain the fluorescence intensity. The analysis module is used to determine whether the fluorescence intensity is within the first threshold interval or greater than the second threshold; if so, predict that the reproductive capacity of the sample is strong; if not, predict that the reproductive capacity of the sample is weak.
[0107] The system also includes a differential gene screening module, which is used to obtain differential genes related to reproduction in the transcriptome of Kazakh horses; and obtain a primer set based on the differential genes.
[0108] The third aspect of the present invention also provides a kit for implementing the above method. The kit includes a primer set for differential genes, and the differential genes include any of the following genes or a combination thereof: COL14A1, COL6A5 and COL3A1. Wherein, the primer set includes Seq ID No.: 3 and Seq ID No.: 4; and Seq ID No.: 1 and Seq ID No.: 2 as internal references. The primer set also includes a fluorescent probe.
[0109] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for predicting horse reproductive performance based on transcriptome sequencing technology, characterized in that: The following steps are involved: To obtain differentially expressed genes related to reproduction in the transcriptome of Kazakh horses; According to the differentially expressed genes, a primer set is obtained; Using the primer set to perform fluorescence quantitative PCR detection on the differential genes of the sample to obtain the fluorescence intensity; Determining whether the fluorescence intensity is within a first threshold interval or greater than a second threshold; If so, it is predicted that the said sample has strong reproductive capacity; If not, the reproductive capacity of the sample is predicted to be weak.
2. The method according to claim 1, characterized in that: The differentially expressed genes include any one of the following genes or a combination thereof: COL14A1, COL6A5 and COL3A1.
3. The method according to claim 1, characterized in that The differential gene is an up-regulated gene, and the fluorescence intensity of the sample to be tested, the standard positive sample and the standard negative sample are obtained respectively; Determine whether the fluorescence intensity of the sample to be tested meets any of the following conditions or their combination: The fluorescence intensity of the sample to be tested is greater than the fluorescence intensity of the standard positive sample*A, and greater than the fluorescence intensity of the standard negative sample, where A is expressed as a coefficient; If it is satisfied, it is judged that the reproductive capacity of the sample to be tested is strong.
4. The method according to claim 3, characterized in that Also included are methods for grading reproductive capacity: According to the fluorescence intensity of the standard positive sample and the standard negative sample, the fluorescence intensity is divided into multiple levels and corresponding threshold intervals; The sample to be tested is matched with the threshold interval to obtain the level of the sample to be tested.
5. The method according to claim 1, characterized in that The primer set includes Seq ID No.:3 and Seq ID No.:
4.
6. The method according to claim 5, characterized in that The primer set also includes Seq ID No.: 1 and Seq ID No.:
2.
7. The method according to claim 5, characterized in that The primer set also includes a Taqman probe.
8. The method according to claim 1, characterized in that: Methods for obtaining differentially expressed genes include: Establishing Kazakh horse groups, including the first and second groups, where the first group has stronger reproductive capacity than the second group; Extracting RNA from each sample in the group, wherein the RNA includes coding RNA and non-coding RNA; Sequencing the RNA to obtain offline data; The offline data are analyzed to obtain differentially expressed genes.
9. The method according to claim 8, characterized in that Methods for obtaining deplaning data include: Remove ribosomal RNA from RNA of each sample; The obtained RNA is randomly broken into short fragments; The fragmented RNA was used as a template to synthesize the first strand of cDNA using six-base random primers; Add buffer, dNTPs, RNase H and DNA polymerase I to the first strand of cDNA to synthesize the second strand of cDNA; After the cDNA is purified and eluted with EB buffer, it is end-repaired and base A is added, and then sequencing adapters are added; Degradation of the second strand by UNG enzyme; After fragment size selection by agarose gel electrophoresis, PCR amplification was performed to obtain a sequencing library; The sequencing library is sequenced by a sequencer to obtain offline data.
10. The method according to claim 8, characterized in that Methods for analyzing disembarkation data include: Filter the offline data to obtain clean data; The read length of the clean data was aligned to the reference genome using the tool Hisat2, and the transcripts were reconstructed using stringtie to obtain known transcripts and new transcripts; Predict the coding capacity of new transcripts to obtain newly predicted long non-coding RNAs and known genes; After analyzing the long non-coding RNA and known genes in the samples respectively, the association analysis between the long non-coding RNA and the known genes was performed.
